7 results about "Toxic proteins" patented technology

The application discloses a kind of short peptides simulating RhoE C end, derivative and its pharmaceutical use in treating ventricular remodeling, belong to biological medicine technical field.The short peptide and derivative contain RhoE C end 200-240 linear function domain, can be combined and activated WWP2, remove HGS self-inhibition, start endosome-lysosome degradation pathway.Short peptide sequence is as SEQ ID NO.1, derivative can be coupled with TAT, T7 or RVG membrane penetrating peptide (SEQ ID NO.2-4), and endocytosed to myocardial cell by caveolin high efficiency delivery.The application solves the defects that existing anti-ventricular remodeling drug inhibits protective autophagy flow, and the ability of eliminating toxic protein is limited, can efficiently eliminate damaged mitochondria and misfolded protein, inhibits myocardial hypertrophy, fibrosis, improves cardiac remodeling, provides safe and effective treatment strategy for related diseases.

To provide an inducible promoter for viral vector production.SOLUTION: Aspects described herein relate to a stable cell line for recombinant viral vector (e.g., recombinant adeno-associated viral vector) production comprising at least one inducible promoter operably linked to a heterologous gene encoding a toxic protein. Further provided herein are methods for generating stable cell lines and methods for viral vector production. The present invention relates to cell lines for the rapid and scalable production of viral vectors, such as adeno-associated virus (AAV).SELECTED DRAWING: None

The application relates to the field of biological information and discloses a toxic protein library construction method, device, equipment and medium. The method comprises the following steps: acquiring a common peptide structure corresponding to a confirmed toxic protein sequence, and constructing a target toxic protein core peptide set capable of covering a key functional domain of the confirmed toxic protein sequence based on function performance characteristic data and fluctuation trend characteristic data of the common peptide structure. The target toxic protein core peptide set is used for function screening of a to-be-recognized protein sequence in a function characteristic domain, so that an intermediate protein sequence needing to be verified whether it meets a toxicity characteristic is obtained, toxicity screening of the intermediate protein sequence in a toxicity characteristic domain is performed, and the intermediate protein sequence meeting the toxicity characteristic is determined as a target toxic protein sequence. Finally, a toxic protein database is constructed by using the target toxic protein sequence. Thus, a toxic protein library construction method with a wide coverage range which can discover new toxic proteins and detect low-abundance toxic proteins is realized through a two-level screening mode combining function screening and toxicity screening.

Disclosed herein are nucleotide sequences encoding an insecticidal protein exhibiting Lepidopteran inhibitory activity, as well as novel insecticidal proteins referred to herein as a BCW 001, BCW 002, BCW 003, and BCW toxic protein-containing chimeras and BCW toxin insecticide, transgenic plants expressing the chimeras or the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample.

The present invention relates to a recombinant plasmid comprising a gene encoding a protein toxic to an organism and a gene encoding an ELP linked thereto. By using the recombinant plasmid, it is possible to produce a fusion protein in an organism in which the toxicity of the protein is mitigated due to fusion with the ELP.

A method, kits, and devices for performing the method of immediately improving and / or restoring the mechanical integrity and material properties of thermally shrunk collagenous tissue through delivery of a non-toxic protein crosslinker to the tissue. A thermal energy device shrinks the target tissue using controlled application of thermal energy. A non-toxic protein crosslinker is injected and / or topically applied to the target tissue before, during, and / or after thermal shrinkage. A dual applicator may comprise a thermal energy probe and injection needle. The thermal energy probe may apply thermal energy to the target tissue and the injection needle may apply the non-toxic protein crosslinker to the target tissue. A kit for use in performing the method may provide various components used for applying thermal energy and applying the non-toxic protein crosslinker to the target tissue.

The present invention belongs to the field of biomedicine, and relates to an siRNA for inhibiting APP gene expression and a conjugate. The siRNA comprises a sense strand and an antisense strand. The sense strand comprises a nucleotide sequence I, and the antisense strand comprises a nucleotide sequence II. Each nucleotide in the nucleotide sequence I and the nucleotide sequence II is a modified or unmodified nucleotide. The nucleotide sequence I and the nucleotide sequence II are at least partially reverse complementary to form a double-stranded region. The nucleotide sequence I is substantially identical to a first nucleotide sequence segment, and the first nucleotide sequence segment is a nucleotide sequence having a length of at least 15 nucleotides in an mRNA expressed by the APP gene. The siRNA of the present invention can specifically induce the degradation of APP mRNA, thereby inhibiting the synthesis of APP, inducing a persistent reduction in APP proteins, and reducing the pathological deposition of associated toxic proteins such as Aβ. The siRNA has a good prospects in becoming medicine.